Innovent Biologics has entered into a significant collaboration with Pfizer, valued at up to US$10.5 billion, to advance 12 cancer drug programs. The deal includes an upfront payment of US$650 million to Innovent, with potential for substantial milestone and royalty payments. Innovent will spearhead the initial phase one trials for all 12 programs, after which Pfizer will take the lead on global development. The partnership also involves joint development and co-commercialization efforts in the US and Europe for some assets, while Innovent retains exclusive rights in China. AI
IMPACT This collaboration could accelerate the development of new cancer therapies, impacting the biopharmaceutical industry.
RANK_REASON This is a significant industry partnership with a large financial value and implications for drug development. [lever_c_demoted from significant: ic=1 ai=0.0]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
